| Name | Ticlopidine hydrochloride |
| Description | Ticlopidine hydrochloride (Ticlodix) is an effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES. |
| In vitro | Oral administration of Ticlopidine HCl in rats enhances the affinity of cyclase on platelet membranes for prostaglandin E1, subsequently activating both the basal and prostaglandin E1-stimulated without affecting the enzyme activity induced by adenosine or sodium fluoride. Ticlopidine HCl exhibits an inhibitory effect on platelet aggregation with an IC50 of 2 μM in males. |
| In vivo | Ticlopidine HCl inhibits platelet aggregation by activating basal PGE1-induced cyclase activity, blocking the enhancement of cyclase activity induced by PGE2, thereby increasing platelet c-AMP levels, and suppressing prostaglandin synthesis from endogenous substrates. Additionally, it alters platelet membrane function and inhibits aggregation through the blockade of ADP receptors. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 30 mg/mL (100 mM)
DMSO : 65 mg/mL (216.49 mM), Sonication is recommended.
|
| Keywords | Ticlopidine Hydrochloride | Inhibitor | P1 receptor | inhibit | Ticlopidine hydrochloride | Adenosine Receptor | Ticlopidine |
| Inhibitors Related | Theophylline monohydrate | Diphylline | Acefylline | Aminophylline | Inosine | Theobromine | Istradefylline | Theophylline | Adenosine antagonist-1 | Doxofylline |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
